Illumina (NASDAQ:ILMN) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Illumina (NASDAQ:ILMN) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating on the life sciences company’s stock.

A number of other brokerages also recently weighed in on ILMN. Robert W. Baird raised their target price on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, July 10th. Citigroup lifted their price target on shares of Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. Finally, UBS Group lifted their price target on shares of Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $151.55.

Illumina Trading Up 2.1 %

Shares of ILMN opened at $122.28 on Tuesday. The firm’s 50 day simple moving average is $114.07 and its 200 day simple moving average is $122.62. The company has a market capitalization of $19.48 billion, a P/E ratio of -15.00 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. Illumina has a 1-year low of $89.00 and a 1-year high of $178.44.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. Illumina’s quarterly revenue was down 5.4% on a year-over-year basis. During the same period last year, the firm posted $0.32 earnings per share. Sell-side analysts forecast that Illumina will post 1.5 earnings per share for the current fiscal year.

Institutional Trading of Illumina

Large investors have recently added to or reduced their stakes in the stock. Trivant Custom Portfolio Group LLC boosted its holdings in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after acquiring an additional 125 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new stake in Illumina in the fourth quarter valued at $37,000. Massmutual Trust Co. FSB ADV boosted its holdings in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. MeadowBrook Investment Advisors LLC bought a new stake in Illumina in the fourth quarter valued at $42,000. Finally, Industrial Alliance Investment Management Inc. bought a new stake in Illumina in the second quarter valued at $34,000. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.